Lymphomas Clinical Trial
Official title:
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Relapsed and Refractory CD30 Positive Lymphomas
Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 represents a very attractive target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will evaluate a novel 4th generation CD30 CAR engineered with a self-withdrawal mechanism (FKBP-iCasp9) for both efficacy and safety evaluation in lymphoma patients.
A large number of lymphoma patients exhaust current treatment options and die from the disease. Innovative therapy is urgently needed. Chimeric antigen receptor (CAR)-modified T cells have demonstrated unprecedented successes in treating even late stage cluster of differentiation antigen 19 (CD19) positive B cell malignancies. Besides CD19 lymphomas, many lymphomas are CD30 positive and therefore, CD30-CAR T cells may prove to be effective in treating such patients. We have developed several generations of CD30 CARs. Preclinical studies have demonstrated effective killing of CD30 target cells. In this study, two versions of CD30 CARs, both of which are 4th generation CARs with a self-withdrawal mechanism (FKBP-iCasp9), will be evaluated in CD30 lymphoma patients. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, tumor targeting and disease status after treatment will also be evaluated. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01359982 -
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
|
Phase 1 | |
| Completed |
NCT02140736 -
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
|
||
| Completed |
NCT00725634 -
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00947739 -
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT00222443 -
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
|
Phase 1 | |
| Recruiting |
NCT02211755 -
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
|
Phase 1 | |
| Completed |
NCT02048488 -
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06148220 -
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
|
N/A | |
| Completed |
NCT01031641 -
Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing
|
||
| Withdrawn |
NCT02786485 -
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
|
Phase 1 | |
| Completed |
NCT01387841 -
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
| Completed |
NCT00396864 -
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
|
Phase 1 | |
| Terminated |
NCT00023166 -
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
|
Phase 1 | |
| Recruiting |
NCT04417803 -
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques
|
N/A | |
| Recruiting |
NCT05775406 -
Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT01836822 -
Bronchoscopic Sampling Techniques in Sarcoidosis
|
N/A | |
| Completed |
NCT02902237 -
tTF-NGR Phase I Study
|
Phase 1 | |
| Completed |
NCT02578316 -
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
|
Phase 1 | |
| Recruiting |
NCT00900198 -
Collection of Tissue Samples for Cancer Research
|
||
| Completed |
NCT02740270 -
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
|
Phase 1 |